NIH Extends Agreement with Galapagos
News Jul 22, 2008
Galapagos NV announced that the U.S. National Institutes of Health (NIH) have extended their agreement with Galapagos' service division BioFocus DPI for the operation of the Molecular Libraries Small Molecule Repository (MLSMR) until December 2010.
According to the terms of this agreement, Galapagos will receive more than $9 million (€5.7 million) over the course of the two year extension.
BioFocus DPI runs a compound management facility for a number of industrial and U.S. government customers out of its Compound Focus, Inc. subsidiary in South San Francisco.
Home to the MLSMR since 2004, this facility acquires and stores compounds under the contract with NIH and distributes these compounds for high-throughput biological screening throughout the NIH's academic network in the U.S.
"We are pleased that the NIH has elected to continue working with BioFocus DPI. Through this extended agreement, the compound management facility has once again demonstrated that it is a leading provider of these services," said Onno van de Stolpe, CEO of Galapagos.
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE